top of page

Biological Quality Assurance

NanoScout's BioQA offering represents a transformative leap forward in the field of microbial analysis. Enabling a multitude of industries to detect, resolve, and diagnose microorganism-related issues at the nanoscale. Our innovative cloud-based artificial intelligence (AI) empowers us to develop and refine algorithms tailored exclusively for our users, delivering solutions that cater to their unique needs.

LEG 1   DIL0026.tiff

Antimicrobial Resistance and Testing

LEG 2   DIL0023.tiff

NanoScout's BioQA offering is not merely a solution; it's a transformative approach to diagnosing and understanding microorganisms at the nanoscale level. In the medical and healthcare sectors, our BioQA offering offers substantial benefits:

Algorithm to enable precise detection and identification of microorganisms, including E. coli, at the nanoscale, which can lead to improved accuracy in diagnostic tests.

Expedite the process of identifying and addressing microbial contamination, which is vital in healthcare settings where timely detection can significantly impact patient outcomes.

Targeted Interventions: The insights gained from our technology allow for more targeted and personalized treatment approaches, which can lead to better patient recovery rates and overall health outcomes.

Antimicrobial Resistance Monitoring: Our platform can be instrumental in monitoring the spread and development of antimicrobial resistance among MRSA, MSSA, E. coli and other bacteria, providing critical data that can inform public health policies and guide the development of more effective antibiotics.

Strep B Sample 2 DIL0056.tiff

Drug Discovery

Our platform's ability to analyze small-scale phenomena opens up new possibilities for the development of precise and personalized treatments, contributing to a significant shift in the way we approach drug discovery.

Surface Level Detection - Nanoparticle and

Antibody Research

By leveraging Scanning Electron Microscopy (SEM) technology, BioQA allows for the observation of nanoparticles to actively search for infections.This innovative approach enables the detection of surface antibodies and phages, which play crucial roles in the immune response against pathogens.

Early Disease Detection

Biomarker analysis gives NanoScout the ability to come to quick diagnosis leading to early intervention and improved outcomes.

ANTHRAX 22 DIL0076.tiff

With NanoScout's BioQA offering, we are taking a significant step towards the future of testing and screening in the wide range of fields. By offering a streamlined, cost-effective, and accurate solution, we are paving the way for efficient and effective  diagnostics and drug discovery. 

bottom of page